SLC16A10 and metabolic dysfunction-associated steatohepatitis: Decreased gene expression of amino acid transporters, such as SLC16A10, was suggested to be a potential mechanism for the elevation of tyrosine levels in NASH patients [24], which could not be verified due to lack of sufficient liver samples.